|Bid||99.18 x 900|
|Ask||101.95 x 800|
|Day's Range||99.46 - 101.80|
|52 Week Range||42.62 - 102.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Humana ...
Dexcom, Inc. (DXCM), a leader in continuous glucose monitoring (CGM), announced today that the company has received CE Mark for its Dexcom G6 System for people with diabetes ages two years and up. “The Dexcom G6 represents the future of diabetes management. Not only does the product eliminate the need for fingersticks, but it also maintains the performance, connectivity and accuracy that the diabetes community has come to expect from Dexcom CGM,” said John Lister, Dexcom’s General Manager for EMEA.
Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is updating its policy on mobile device compatibility for the Dexcom G5® CGM System. Available on iOS and Android, the Dexcom G5 is the first and only mobile-enabled CGM system for Medicare patients with diabetes that works to display and share real-time glucose activity. Medicare’s published coverage policy for CGMs will be modified to support the use of CGMs in conjunction with a smartphone, including the important data sharing function they provide for patients and their families.
SALEM, N.H. and WILSONVILLE, Ore., June 5, 2018 /PRNewswire/ -- AgaMatrix, Inc., a developer of diagnostic technologies for glucose monitoring and wholly owned subsidiary of AgaMatrix Holdings LLC, announced a prevailing outcome in a retaliatory patent infringement lawsuit brought by Dexcom, Inc. (NASDAQ: DXCM). In a decision ruled earlier this year by the US District Court for the Central District of California, the honorable Judge S. James Otero granted summary judgment of non-infringement in favor of AgaMatrix, citing that AgaMatrix did not infringe upon Dexcom's U.S. Patent No 7,081,195.
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).
NEW YORK, April 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: Cancer Genetics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free earnings report on DexCom, Inc. (NASDAQ: DXCM ). If you want ...
DexCom, Inc. today announced that it plans to release its first quarter 2018 financial results after market close on Wednesday, May 2, 2018. Management will hold a conference call to review the company's first quarter 2018 performance starting at 4:30 p.m.
DexCom, Inc. , the leader in continuous glucose monitoring is pleased to announce that the U.S. Food and Drug Administration has granted a De Novo request for the Dexcom G6® CGM System, the newest generation of CGM for people with diabetes ages 2 and up.
NEW YORK, NY / ACCESSWIRE / March 26, 2018 / Rising concerns over a potential trade war with China continued to drag markets down on Friday, with the Dow Jones plummeting more than 400 points. The Dow ...
The US Patent Office Patent Trial and Appeal Board recently ruled to uphold the validity of WaveForm Technologies Inc. patents in the emerging field of continuous glucose monitoring SALEM, N.H. and WILSONVILLE, ...
DexCom, Inc. today reported its financial results as of and for the quarter and fiscal year ended December 31, 2017.
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / DexCom, Inc. (NASDAQ: DXCM ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern Time. ...
DexCom, Inc. (DXCM), has today released the findings of the HypoDE study, a multi-centre, randomised controlled trial (RCT) which was discussed on Friday 15th February at ATTD. The study found that the use of Dexcom continuous glucose monitoring (CGM) reduces the frequency and severity of hypoglycaemic events among high-risk individuals with type 1 diabetes treated with multiple daily injections (MDI) of insulin. Hypoglycaemia remains a key limiting factor in achieving optimal glycaemic control in people with type 1 diabetes, and the vast majority of these individuals are treated with MDI globally.
DexCom, Inc. today announced that management will present an update on DexCom at the following upcoming investor conferences:
DexCom, Inc. today announced that it plans to release its fourth quarter and full year 2017 financial results after market close on Tuesday, February 27, 2018. Management will hold a conference call to review the company's fourth quarter and full year 2017 performance starting at 4:30 p.m.
UnitedHealthcare, the market leader in Medicare benefit plans1, and DexCom, Inc., the leader in continuous glucose monitoring for diabetes management, today announced an individualized glucose management pilot program driven by wearable technology to help people with Type 2 diabetes manage their condition in real time.
DexCom, Inc. , the leader in continuous glucose monitoring , today reported that it achieved preliminary, unaudited revenue of approximately $218 million for the fourth quarter ended December 31, 2017, an increase of 27% over the fourth quarter of 2016.
DexCom, Inc. , the leader in continuous glucose monitoring for people with diabetes, today announced a development agreement with Eli Lilly and Company to include Dexcom CGM into Lilly’s Connected Diabetes Ecosystem.